Lexology October 24, 2024
McGuireWoods LLP

On Sept. 18, 2024, the U.S. Food & Drug Administration (FDA) issued a final guidance document titled “Conducting Clinical Trials With Decentralized Elements, Guidance for Industry, Investigators, and Other Interested Parties”(CTDE guidance). The final guidance, which builds upon a prior draft guidance document issued in May 2023, provides valuable insight into a host of issues implicated by decentralized clinical trials (DCTs). It also reflects the FDA’s continued support for well designed and implemented DCTs and underscores the benefits that trials with decentralized elements can provide to trial participants, industry members and healthcare consumers. This article provides an overview of the guidance and discusses key takeaways for industry members, investors and other stakeholders.

Decentralized Clinical Trials

While DCTs are not new...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Clinical Trials, FDA, Govt Agencies, Trends
Related Articles:
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments

Share This Article